A solution for activating or suppressing immune responses to any antigen.

  • Multi antigen and immunomodulator codelivery
  • Repeatable administration by any route
  • Fully synthetic, rapid manufacturing, reliable results

SNAPvax applications

SNAPvax tolerance vaccine (TV)

  • Autoantigens and immunomodulators codelivered to tolerogenic immune cells
  • Induces antigen-specific regulatory T cells providing a mild, potentially curative therapy for allergies & autoimmunity

SNAPvax cancer vaccine (CV)

  • Targeting of any tumor antigens (including PTMs) to induce anticancer T cells & antibodies
  • T cell priming + repeat administration by the intravenous route to engage every stage of the cancer immunity cycle for maximal benefit

SNAPvax antibody vaccine (AV)

  • Array of any minimal immunogen, including glycopeptides (not possible with RNA or viruses)
  • Focuses antibodies to conserved epitopes (minimal immunogens) thereby preventing escape and off-target toxicity



SNAPvax overcomes key limitations of conventional vaccine approaches.

Expression systems
(e.g., adenovirus, RNA)

Avidea's SNAPvax

Key challenges

  • Unable to target PTMs (e.g., glycopeptides)
  • Inherently pro-inflammatory (challenge for tolerance)
  • Immunomodulators limited to biologics
  • Anti-vector antibodies can prevent repeat administration
  • Narrow therapeutic index for IV administration
  • Recombinant, high mfg. costs, stability challenges with RNA


  • Can target any antigen (including PTMs)
  • Inert carrier enables programmable immune response
  • Capable of delivering key immunomodulators
  • Can be repeatedly administered to maintain immunity
  • IV administration (key for cancer treatment)
  • Fully synthetic, low-cost mfg., highly stable

Conventional nanoparticles
(e.g., liposome and PLGA particles)

Avidea's SNAPvax

Key challenges

  • Weakly immunogenic for inducing T cells
  • Variable drug loading, challenge for multi-antigen vaccines
  • Major mfg. challenges, including sterile filtration


  • Most efficient platform reported to-date for inducing T cells
  • Programmable, precise drug loading, no variability
  • Purpose-built to enable rapid and reliable vaccine manufacturing

Avidea's products are built on strong scientific principles

Scientific principles underlying technology platforms

In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicity.

Read more

Description of SNAPvax as a platform for promoting T cell immunity

Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.

Read more

Immunological mechanisms for enhanced efficacy by intravenous vaccination

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.

Read more

Highly tunable and rapidly translatable

Modular platform allows facile hypothesis testing with myriad combinations of antigens, immunomodulators & targeting ligands

Proven design enables rapid manufacturing of vaccine candidates with high likelihood of success

Established cGMP processes, validated, rapid on-demand manufacturing